Tag: Colorectal Cancer

Microenvironmental CTHRC1 has a pro-tumorigenic role in colorectal cancer

Protein in Tumor Microenvironment Found to Promote Colorectal Cancer Growth and Immune Evasion

June 2, 2026

“These results identify CTHRC1 as a key driver of CRC that may suppress the immune system, allowing for easier immune evasion by tumor cells, highlighting CTHRC1 as a potential new… read more

Oncotarget

Colorectal Cancer Survival Predicted by AI Using Clinical and Molecular Features

December 17, 2025

“The clinical and biological features proposed here in conjunction with ML can improve the interpretation of CRC mechanisms and predict patient survival.” BUFFALO, NY - December 17, 2025 – A… read more

Oncotarget

Cholesterol-Lowering Drugs Show Promise Against Colorectal Cancer

July 22, 2025

“Our findings provide direct evidence that statins selectively modulate key components of the Wnt/β-catenin signaling pathway, a major driver of adenoma formation, including members of the special AT-rich sequence-binding (SATB)… read more

Oncotarget

WIN International Molecular Tumor Board Recommends Tailored Treatment for Advanced Colorectal Cancer

June 24, 2025

“This case emphasizes the critical role of comprehensive molecular profiling and personalized therapeutic approaches in managing complex mCRC.” BUFFALO, NY - June 24, 2025 – A new precision oncology paper… read more

Oncotarget

New Study Suggests Panitumumab with Low-Dose Capecitabine as a Safer, Effective Maintenance Treatment for Advanced Colorectal Cancer

February 18, 2025

“Using Panitumumab with metronomic Capecitabine is considered an accepted maintenance regimen in wild type Ras metastatic colorectal cancer regardless of the primary site.” BUFFALO, NY - February 18, 2025 –… read more

Oncotarget

Tracking cfDNA Release Dynamics During Colorectal Cancer Surgery

January 27, 2025

“Taken together, our results suggest that in addition to physiological age, comorbidities and unfavorable clinical traits, intense surgical manipulation from the tumor's extent, may result in greater tissue damage and… read more

Oncotarget

Genotype Matters: Tailored Screening for Germline CHEK2 Variants

August 26, 2024

“In our study, we postulated that these differences were driven by three common low-risk (LR) missense variants: p.I157T, p.S428F, and p.T476M, all of which have a BC odds ratio of… read more

Oncotarget

Role of the Gut Barrier in Colorectal Cancer Treatment

August 19, 2024

“Herein we discuss how gut microbiota and microbial metabolites regulate basal inflammation levels in the gut and the healing process of the bowel after surgery.” BUFFALO, NY- August 19, 2024… read more

Oncotarget

Behind the Study: HER3: A Vital Target in Cancer Treatment

October 12, 2023

Dr. Omkar Desai from the Department of Surgery at Case Western Reserve University and University Hospitals Cleveland Medical Center, describes a research perspective he co-authored with Dr. Rui Wang that… read more

Oncotarget

Suppression of Cancer Stemness and Drug Resistance via BRAF/EGFR/MEK Inhibition in Colorectal Cancer Cells

October 11, 2023

“[...] our approach enables mechanistic studies of drug resistance with 3D cultures of primary cancer cells to develop and test treatments that suppress cancer [...].” BUFFALO, NY- October 11, 2023… read more